"Painkillers Market Will Reach $61.6 Billion in 2012" Visiongain Report Predicts
A new report by visiongain predicts that the world market for drugs to relieve pain will reach $61.6 billion for 2012. That revenue forecast appears in World Pain Relieving Drug Market 2012-2022, published in September 2012. Visiongain is a business information provider based in London, UK.
London, United Kingdom, September 13, 2012 --(PR.com)-- The study forecasts that the overall market for pain relieving drugs will grow steadily from 2012 to 2022. The world pain-treating drug market is a high-revenue industry with a high public and healthcare profile. Market growth will be stimulated by rises in disease prevalence, ageing populations and prevalence of cancer, arthritis and diabetes.
Growth of the pain treatment market will be stimulated by new drugs and reformulations of existing products from 2012 onwards. The launch of new treatments, including more-efficacious drugs, improved drug delivery and new dosing schedules, will increase revenues. Visiongain believes that increasing public awareness and the development of submarkets such as neuropathic and cancer pain treatment will be crucial to expansion of the industry and market.
Dr Peter Williamson, a pharmaceutical industry analyst in visiongain, said: “Pain is a prevalent condition with huge socio-economic consequences. Many people need pain relief to complete everyday tasks. To achieve more-efficient pain relief, a better understanding of its underlying mechanisms and causes are needed, which, in turn, will lead to more pain therapies being tailored to a specific pain type. The high growth rate of the neuropathic pain market is a good example. Also, drug approvals for neuropathic indications are becoming more frequent. Importantly, the pharma industry has many promising R&D pipeline candidates for pain relief.”
Visiongain’s report shows revenue forecasts to 2022 at overall world market, submarket, product and national level. The study includes OTC (over-the-counter) and Rx (prescription) pain relieving medicines. It forecasts these world-level submarkets:
• Narcotics
• Non-narcotics
• Neuropathic pain relievers
• Treatments for migraines
• Treatments for arthritis.
The investigation predicts revenues of 28 leading drugs in the painkillers market, including Oxycontin ER, Panadol, Lyrica and Zomig. Research, data and analyses cover activities of Pfizer, GSK, Johnson & Johnson, Bristol-Myers Squibb and other pharmaceutical companies.
That report discusses R&D and commercial news, shows research interviews and forecasts revenues in leading national markets. The work analyses the US, Japan, five leading EU countries (the EU5), India and China.
World Pain Relieving Drug Market 2012-2022 adds to visiongain’s range of analytical reports on industries and markets in healthcare.
For sample pages and further information concerning the World Pain Relieving Drug Market 2012-2022 please visit: http://www.visiongain.com/Report/867/World-Pain-Relieving-Drug-Market-2012-2022
For an executive summary of this report or to order it today please contact:
Email: Sara Peerun on sara.peerun@visiongainglobal.com
Tel: +44 (0) 20 7336 6100
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100
About visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.
Growth of the pain treatment market will be stimulated by new drugs and reformulations of existing products from 2012 onwards. The launch of new treatments, including more-efficacious drugs, improved drug delivery and new dosing schedules, will increase revenues. Visiongain believes that increasing public awareness and the development of submarkets such as neuropathic and cancer pain treatment will be crucial to expansion of the industry and market.
Dr Peter Williamson, a pharmaceutical industry analyst in visiongain, said: “Pain is a prevalent condition with huge socio-economic consequences. Many people need pain relief to complete everyday tasks. To achieve more-efficient pain relief, a better understanding of its underlying mechanisms and causes are needed, which, in turn, will lead to more pain therapies being tailored to a specific pain type. The high growth rate of the neuropathic pain market is a good example. Also, drug approvals for neuropathic indications are becoming more frequent. Importantly, the pharma industry has many promising R&D pipeline candidates for pain relief.”
Visiongain’s report shows revenue forecasts to 2022 at overall world market, submarket, product and national level. The study includes OTC (over-the-counter) and Rx (prescription) pain relieving medicines. It forecasts these world-level submarkets:
• Narcotics
• Non-narcotics
• Neuropathic pain relievers
• Treatments for migraines
• Treatments for arthritis.
The investigation predicts revenues of 28 leading drugs in the painkillers market, including Oxycontin ER, Panadol, Lyrica and Zomig. Research, data and analyses cover activities of Pfizer, GSK, Johnson & Johnson, Bristol-Myers Squibb and other pharmaceutical companies.
That report discusses R&D and commercial news, shows research interviews and forecasts revenues in leading national markets. The work analyses the US, Japan, five leading EU countries (the EU5), India and China.
World Pain Relieving Drug Market 2012-2022 adds to visiongain’s range of analytical reports on industries and markets in healthcare.
For sample pages and further information concerning the World Pain Relieving Drug Market 2012-2022 please visit: http://www.visiongain.com/Report/867/World-Pain-Relieving-Drug-Market-2012-2022
For an executive summary of this report or to order it today please contact:
Email: Sara Peerun on sara.peerun@visiongainglobal.com
Tel: +44 (0) 20 7336 6100
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100
About visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.
Contact
Visiongain
Sara Peerun
+44 020 7336 6100
www.visiongain.com
Sara Peerun
+44 020 7336 6100
www.visiongain.com
Contact
Categories